Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609718 | 0.88 | RXRA (0.40) | RXRAGRIN1GRIN2BKMT2ALMNA | |
| SCHEMBL2327869 | 0.80 | DRD1 (0.49) | RXRAGRIN1GRIN2BKMT2ALMNA | |
| SCHEMBL31134139 | 0.77 | LMNA (0.32) | KMT2ALMNAGRM4 | |
| SCHEMBL355299 | 0.76 | MAP4K4 (0.38) | KMT2ALMNAKDM4EALDH1A1HPGD | |
| SCHEMBL29434486 | 0.76 | RXRA (0.33) | RXRAGRIN1GRIN2BKMT2ALMNA | |
| SCHEMBL15933172 | 0.76 | RXRA (0.35) | RXRAGRIN1GRIN2BMAPTHDAC4 | |
| SCHEMBL21275802 | 0.76 | ROCK1 (0.41) | RXRAGRIN1GRIN2BKMT2ALMNA | |
| SCHEMBL29433330 | 0.76 | CHRNA3 (0.41) | KMT2ALMNA | |
| SCHEMBL15738713 | 0.76 | CHRNA3 (0.41) | KMT2ALMNA | |
| SCHEMBL9583581 | 0.74 | CHRNB2 (0.38) | RXRAGRIN1GRIN2BKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120476110-B | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | SHANGHAI HANSOH BIOMEDICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122079878-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079879-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079880-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3911640-B1 | PCSK9 INHIBITORS FOR USE IN THERAPY, ESPECIALLY THE TREATMENT OF CARDIOVASCULAR DISEASE | ASTRAZENECA AB (SE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4741376-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12612403-B2 | Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | ASTRAZENECA AB (SE) | 2026-03-24 | — | — | US | disclosed |
| WO-2026041663-A1 | P2X7 RECEPTOR ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2026-02-26 | — | — | WO | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | RXRA 334/4885GRIN1 48/4885GRIN2B 53/4885 |
| US-12612403-B2 | Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof | FAR1, NPR1, CBR1 | RXRA 4512/4885GRIN1 943/4885GRIN2B 2635/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | RXRA 334/4885GRIN1 48/4885GRIN2B 53/4885 |
| US-12584120-B2 | PCSK9 inhibitors and methods of use thereof | PCSK9, LDLR, PCSK7 | RXRA 1670/4885GRIN1 3881/4885GRIN2B 3923/4885 |
| US-20260085045-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NPR1, CBR1, NAT1 | RXRA 1170/4885GRIN1 45/4885GRIN2B 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.